Takuya Komeno
Mito, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Expression of functionally glycosylated PSGL-1 in ALK-positive anaplastic large cell lymphoma.
Journal: Pathology, research and practice
Published: January 27, 2025
A phase 2 trial of VRD induction for transplant-eligible Japanese patients with newly diagnosed multiple myeloma.
Journal: International journal of hematology
Published: November 28, 2024
A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM.
Journal: International journal of hematology
Published: August 27, 2024
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
Journal: International journal of hematology
Published: November 16, 2021
Impact of the Clinical Trials Act on Noncommercial Clinical Research in Japan: An Interrupted Time-series Analysis.
Journal: Journal of epidemiology
Published: October 25, 2021
Acquired platelet dysfunction with severe bleeding tendency in triple-negative myelofibrosis
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: October 07, 2021
The Conspicuousness of High Endothelial Venules in Angioimmunoblastic T-cell Lymphoma Is Due to Increased Cross-sectional Area, Not Increased Distribution Density.
Journal: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
Published: October 07, 2021
Primary Intramuscular Classic Hodgkin Lymphoma: A Rare Case Report.
Journal: Internal medicine (Tokyo, Japan)
Published: June 07, 2021
A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
Journal: International journal of clinical oncology
Published: June 02, 2021
Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years.
Journal: Nagoya journal of medical science
Published: November 25, 2020
Phase II study of dose-adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B-cell lymphoma patients.
Journal: EJHaem
Published: September 11, 2020
Last Updated: 09/26/2026